{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T04:48:01Z","timestamp":1789274881614,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Saudi Pharmaceutical Journal"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jsps.2024.101989","type":"journal-article","created":{"date-parts":[[2024,2,15]],"date-time":"2024-02-15T07:16:27Z","timestamp":1707981387000},"page":"101989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Improvement of comorbid anxiety and depression in patients with migraine treated with injectable preventive calcitonin gene-related peptide antagonists: Review of clinical evidence"],"prefix":"10.1007","volume":"32","author":[{"given":"Abubker","family":"Omaer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulrazaq","family":"Albilali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"Bamogaddam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fares","family":"Almutairi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghad","family":"Alsaif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osama","family":"Almohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah A","family":"Alhifany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"10.1016\/j.jsps.2024.101989_b0010","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/0333102420905132","article-title":"Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)","volume":"40","author":"Ashina","year":"2020","journal-title":"Cephalalgia."},{"key":"10.1016\/j.jsps.2024.101989_b0015","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1001\/jama.1994.03520100096046","article-title":"DSM-IV: diagnostic and statistical manual of mental disorders","volume":"272","author":"Bell","year":"1994","journal-title":"JAMA."},{"key":"10.1016\/j.jsps.2024.101989_b0020","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/hup.2526","volume":"31","author":"Bobo","year":"2016","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.jsps.2024.101989_b0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0165-1781(91)90102-U","article-title":"Migraine, psychiatric disorders, and suicide attempts: an epidemiologic study of young adults","volume":"37","author":"Breslau","year":"1991","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jsps.2024.101989_b0030","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ncl.2019.06.001","article-title":"Migraine: epidemiology, burden, and comorbidity","volume":"37","author":"Burch","year":"2019","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.jsps.2024.101989_b0035","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1007\/s00415-012-6725-x","article-title":"Psychiatric comorbidities of episodic and chronic migraine","volume":"260","author":"Buse","year":"2013","journal-title":"J. Neurol."},{"key":"10.1016\/j.jsps.2024.101989_b0040","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/00004583-199403000-00009","article-title":"Reliability and validity of the Hamilton anxiety rating scale in an adolescent sample","volume":"33","author":"Clark","year":"1994","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry."},{"key":"10.1016\/j.jsps.2024.101989_b0045","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s40259-022-00530-0","article-title":"Calcitonin gene-related peptide (CGRP)-targeted monoclonal antibodies and antagonists in migraine: current evidence and rationale","volume":"36","author":"Cohen","year":"2022","journal-title":"BioDrugs."},{"key":"10.1016\/j.jsps.2024.101989_b0050","doi-asserted-by":"crossref","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","article-title":"Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study","volume":"91","author":"Detke","year":"2018","journal-title":"Neurology."},{"key":"10.1016\/j.jsps.2024.101989_b0055","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1177\/0333102418759786","article-title":"ARISE: A Phase 3 randomized trial of erenumab for episodic migraine","volume":"38","author":"Dodick","year":"2018","journal-title":"Cephalalgia."},{"key":"10.1016\/j.jsps.2024.101989_b0060","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1016\/S0140-6736(19)31946-4","article-title":"Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial","volume":"394","author":"Ferrari","year":"2019","journal-title":"Lancet."},{"key":"10.1016\/j.jsps.2024.101989_b0065","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/head.13010","article-title":"Untangling the association between migraine, pain, and anxiety: examining migraine and generalized anxiety disorders in a Canadian population based study","volume":"57","author":"Fuller-Thomson","year":"2017","journal-title":"Headache."},{"key":"10.1016\/j.jsps.2024.101989_b0070","doi-asserted-by":"crossref","first-page":"e0199750","DOI":"10.1371\/journal.pone.0199750","article-title":"Validity and reliability of the beck depression inventory (BDI-II) in general and hospital population of Dominican Republic","volume":"13","author":"Garc\u00eda-Batista","year":"2018","journal-title":"PLOS ONE."},{"key":"10.1016\/j.jsps.2024.101989_b0080","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","article-title":"A controlled trial of erenumab for episodic migraine","volume":"377","author":"Goadsby","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsps.2024.101989_b0085","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1046\/j.1468-2982.1998.1807455.x","article-title":"Headache and psychiatric comorbidity: clinical aspects and outcome in an 8-year follow-up study","volume":"18","author":"Guidetti","year":"1998","journal-title":"Cephalalgia."},{"key":"10.1016\/j.jsps.2024.101989_b0090","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrneurol.2010.127","article-title":"CGRP and its receptors provide new insights into migraine pathophysiology","volume":"6","author":"Ho","year":"2010","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jsps.2024.101989_b0095","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1212\/WNL.0000000000000771","article-title":"Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention","volume":"83","author":"Ho","year":"2014","journal-title":"Neurology."},{"key":"10.1016\/j.jsps.2024.101989_b0100","doi-asserted-by":"crossref","first-page":"8286","DOI":"10.1038\/s41598-021-87352-2","article-title":"Impact of monthly headache days on anxiety, depression and disability in migraine patients: results from the Spanish Atlas","volume":"11","author":"Irimia","year":"2021","journal-title":"Sci. Rep. Atlas Press."},{"key":"10.1016\/j.jsps.2024.101989_b0105","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1526-4610.2007.00993.x","article-title":"Comorbidity of migraine and psychiatric disorders\u2014a national population-based study","volume":"48","author":"Jette","year":"2008","journal-title":"Headache."},{"key":"10.1016\/j.jsps.2024.101989_b0110","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.jsps.2024.101989_b0115","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12883-021-02123-w","article-title":"Long-term safety and tolerability of eptinezumab in patients with chronic migraine: a 2-year, open-label, phase 3 trial","volume":"21","author":"Kudrow","year":"2021","journal-title":"BMC Neurol."},{"key":"10.1016\/j.jsps.2024.101989_b0120","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s10194-022-01470-4","article-title":"Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials","volume":"23","author":"Lampl","year":"2022","journal-title":"J. Headache Pain."},{"key":"10.1016\/j.jsps.2024.101989_b0125","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.pain.2005.09.010","article-title":"Anxiety and depression associated with migraine: influence on migraine subjects\u2019 disability and quality of life, and acute migraine management","volume":"118","author":"Lant\u00e9ri-Minet","year":"2005","journal-title":"Pain."},{"key":"10.1016\/j.jsps.2024.101989_b0130","doi-asserted-by":"crossref","unstructured":"Lipton, R.B., Bigal, M.E., Diamond, M., Freitag, F., Reed, M.L., Stewart, W.F., AMPP Advisory Group, 2007. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 68, 343\u2013349. 10.1212\/01.wnl.0000252808.97649.21.","DOI":"10.1212\/01.wnl.0000252808.97649.21"},{"key":"10.1016\/j.jsps.2024.101989_b0145","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/head.14097","article-title":"Effects of fremanezumab in patients with chronic migraine and comorbid depression: subgroup analysis of the randomized HALO CM study","volume":"61","author":"Lipton","year":"2021","journal-title":"Headache."},{"key":"10.1016\/j.jsps.2024.101989_b0150","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/j.1468-2982.2007.01446.x","article-title":"The GRIM2005 study of migraine consultation in France ii. Psychological factors associated with treatment response to acute headache therapy and satisfaction in migraine","volume":"27","author":"Lucas","year":"2007","journal-title":"Cephalalgia."},{"key":"10.1016\/j.jsps.2024.101989_b0155","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0165-0327(88)90072-9","article-title":"The Hamilton Anxiety Scale: reliability, validity and sensitivity to change in anxiety and depressive disorders","volume":"14","author":"Maier","year":"1988","journal-title":"J. Affect. Disord."},{"issue":"15","key":"10.1016\/j.jsps.2024.101989_b0160","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1212\/WNL.94.15_supplement.1383","article-title":"Changes in depression and anxiety in a randomized, double-blind, placebo-controlled study of galcanezumab in adults with treatment-resistant migraine: results from the CONQUER study (1383)","volume":"94","author":"Maizels","year":"2020","journal-title":"Neurology."},{"issue":"1","key":"10.1016\/j.jsps.2024.101989_b0165","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s42399-023-01622-w","article-title":"Comorbidity of sleep disorders, mental illness, and migraine or headaches","volume":"5","author":"Merrill","year":"2023","journal-title":"SN Comprehensive Clinical Medicine"},{"issue":"1","key":"10.1016\/j.jsps.2024.101989_b0170","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s42399-023-01452-w","article-title":"Hellenic Headache Society Recommendations for the Use of Monoclonal Antibodies Targeting the Calcitonin Gene-Related Peptide Pathway for the Prevention of Migraine and Cluster Headache\u20142023 Update","volume":"5","author":"Mitsikostas","year":"2023","journal-title":"SN Comprehensive Clinical Medicine"},{"key":"10.1016\/j.jsps.2024.101989_b0175","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1600-0447.1997.tb09649.x","article-title":"Sensitivity of the six-item Hamilton Depression Rating Scale","volume":"95","author":"O\u2019Sullivan","year":"1997","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jsps.2024.101989_b0185","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1468-2982.2004.00830.x","article-title":"The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers","volume":"25","author":"Petersen","year":"2005","journal-title":"Cephalalgia."},{"key":"10.1016\/j.jsps.2024.101989_b0190","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/03007995.2022.2059975","article-title":"Long-term treatment with galcanezumab in patients with chronic migraine: results from the open-label extension of the REGAIN study","volume":"38","author":"Pozo-Rosich","year":"2022","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.jsps.2024.101989_b0195","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s10194-020-01143-0","article-title":"Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: A comprehensive real-world experience","volume":"21","author":"Russo","year":"2020","journal-title":"J. Headache Pain."},{"issue":"1","key":"10.1016\/j.jsps.2024.101989_b0200","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s10194-022-01431-x","article-title":"European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention \u2013 2022 update","volume":"23","author":"Sacco","year":"2022","journal-title":"The Journal of Headache and Pain"},{"key":"10.1016\/j.jsps.2024.101989_b0205","doi-asserted-by":"crossref","first-page":"678","DOI":"10.3389\/fneur.2019.00678","article-title":"Response predictors in chronic migraine: medication overuse and depressive symptoms negatively impact onabotulinumtoxin-a treatment","volume":"10","author":"Schiano di Cola","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jsps.2024.101989_b0210","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/head.14302","article-title":"Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo-controlled randomized clinical trials","volume":"62","author":"Schim","year":"2022","journal-title":"Headache."},{"key":"10.1016\/j.jsps.2024.101989_b0215","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s10194-015-0583-8","article-title":"Validation of the Generalized Anxiety Disorder-7 (GAD-7) and GAD-2 in patients with migraine","volume":"16","author":"Seo","year":"2015","journal-title":"J. Headache Pain."},{"key":"10.1016\/j.jsps.2024.101989_b0220","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s10194-015-0552-2","article-title":"Validation of the Patient Health Questionnaire-9 (PHQ-9) and PHQ-2 in patients with migraine","volume":"16","author":"Seo","year":"2015","journal-title":"J. Headache Pain."},{"key":"10.1016\/j.jsps.2024.101989_b0225","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/occmed\/kqv043","article-title":"The Hamilton rating scale for depression","volume":"65","author":"Sharp","year":"2015","journal-title":"OCCMED."},{"key":"10.1016\/j.jsps.2024.101989_b0230","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s10194-022-01436-6","article-title":"Galcanezumab effect on \u201cwhole pain burden\u201d and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience","volume":"23","author":"Silvestro","year":"2022","journal-title":"J. Headache Pain."},{"key":"10.1016\/j.jsps.2024.101989_b0235","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1177\/0333102418779543","article-title":"Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial","volume":"38","author":"Skljarevski","year":"2018","journal-title":"Cephalalgia."},{"key":"10.1016\/j.jsps.2024.101989_b0240","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.jsps.2024.101989_b0245","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","article-title":"Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial","volume":"75","author":"Stauffer","year":"2018","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jsps.2024.101989_b0250","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s10194-020-01214-2","article-title":"Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment \u2013 real world outcomes","volume":"22","author":"Talbot","year":"2021","journal-title":"J. Headache Pain."},{"key":"10.1016\/j.jsps.2024.101989_b0255","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1590\/1516-4446-2012-1048","article-title":"Psychometric properties of the Beck Depression Inventory-II: A comprehensive review","volume":"35","author":"Wang","year":"2013","journal-title":"Braz J Psychiatry."},{"issue":"Supplement 2","key":"10.1016\/j.jsps.2024.101989_b0260","doi-asserted-by":"crossref","first-page":"II6","DOI":"10.1007\/BF03035120","article-title":"Standardizing the Hamilton Depression Rating Scale: past, present, and future","volume":"251","author":"Williams","year":"2001","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"10.1016\/j.jsps.2024.101989_b0265","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jns.2016.11.071","article-title":"Migraine affects 1 in 10 people worldwide featuring recent rise: A systematic review and meta-analysis of community-based studies involving 6 million participants","volume":"372","author":"Woldeamanuel","year":"2017","journal-title":"J. Neurol. Sci."}],"container-title":["Saudi Pharmaceutical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016424000392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016424000392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T12:24:55Z","timestamp":1736166295000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1319016424000392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S1319016424000392"],"URL":"https:\/\/doi.org\/10.1016\/j.jsps.2024.101989","relation":{},"ISSN":["1319-0164"],"issn-type":[{"value":"1319-0164","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Improvement of comorbid anxiety and depression in patients with migraine treated with injectable preventive calcitonin gene-related peptide antagonists: Review of clinical evidence","name":"articletitle","label":"Article Title"},{"value":"Saudi Pharmaceutical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsps.2024.101989","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V. on behalf of King Saud University.","name":"copyright","label":"Copyright"}],"article-number":"101989"}}